CD274 and non-small cell lung carcinoma: Finally, Pembrolizumab can be given, regardless of PD-L1 status, in combination with pemetrexed and platinum-based chemotherapy in nonsquamous NSCLC or in combination with carboplatin and paclitaxel or nab-paclitaxel in squamous NSCLC.